Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma
Precision Medicine to Target Cancer
At Revive Research Institute, we aim to apply novel approaches to oncology therapies and innovative trial designs, including supportive (medical devices) and therapeutic clinical trials.
According to the American Cancer Society, Follicular lymphoma is among the most common subtypes of non-Hodgkin’s lymphoma (NHL), comprising approximately 22% of NHL cases. With standard treatment options, there is a low chance for cancer regression. However, participation in a clinical trial utilizing new, innovative therapies may provide a possible promising alternative treatment.
At Revive, we believe in improving the quality of life and letting the challenge of cancer clinical research pave the way to innovative therapies that save lives. This novel therapy aims to induce tumor regression and delay tumor progression to control disease-related symptoms and allow maintenance of a good quality of life.
Play your part in improving your life and countless others as well. Your participation can nudge these prospective therapies into a reality.
Participation Criteria:
- Diagnosed with Follicular Non-Hodgkin’s Lymphoma.
- Must be 18 years or older.
- Be willing to comply with study-related procedures.
- Additional Criteria may apply.
Qualified research participants may receive financial compensation for their time and travel, study-related medical and psychological evaluations, and investigative study medication at no cost.